25 May 2013
Keywords: novartis, rasilez, gets, nod, emea, swiss, drug
Article | 02 July 2007
Swiss drug major Novartis has received a positive opinion recommending European Union approval of Rasilez (aliskiren) as the first new ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 July 2007
24 May 2013
© 2013 thepharmaletter.com